Neuronetics (STIM) reported $149M in revenue for fiscal 2025, +99.2% year on year. That ranks #2791 by revenue among 2853 SEC filers and #308 in Healthcare. It posted a net loss of −$39.0M for the same year. Revenue has grown 17.8% a year on average since 2016 ($34.2M then). The fiscal 2025 balance sheet shows $142M in total assets, $28.1M in cash and $65.8M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $149M | +99.2% | FY20252025-12-31 |
| Gross profitGrossProfit | $72.3M | +33.5% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$31.4M | +$3.1M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$39.0M | +$4.7M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$20.4M | +$10.6M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquireProductiveAssets | $801,000 | −45.4% | FY20252025-12-31 |
| Total assetsAssets | $142M | +0.5% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $22.4M | −19.2% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $28.1M | +52.4% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $65.8M | +19.3% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $34.5M | −$10.8M | Open → |
| Q2 20262026-06-30 | $41.6M | −$3.4M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Neuronetics, Inc.
- Ticker
- STIM
- Exchange
- Nasdaq
- SIC classification
- Surgical & Medical Instruments & Apparatus (3841)
- Fiscal year end
- 12-31
- CIK
- 0001227636
Filings
- 10-QAug 11, 2026Open filing →
- 10-QMay 5, 2026Open filing →
- 10-KMar 17, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Heron TherapeuticsHRTX | $155M | −$20.0M |
| Airsculpt TechnologiesAIRS | $152M | −$11.7M |
| MacrogenicsMGNX | $150M | −$74,620 |
| NeuroneticsSTIM | $149M | −$39.0M |
| Elite PharmaceuticalsELTP | $149M | $44.9M |
| GrailGRAL | $147M | −$408M |
| Cronos GroupCRON | $147M | −$2.9M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Neuronetics — Key figures |url=https://companiesranked.com/en/company/neuronetics |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Neuronetics — Key figures. CompaniesRanked. https://companiesranked.com/en/company/neuroneticsBibTeX
@misc{companiesranked-en-company-neuronetics-2026,
author = {{CompaniesRanked}},
title = {{Neuronetics — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/neuronetics}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001104659-26-029004 · March 17, 2026
{{cite web |title=Neuronetics — Key figures — 10-K (0001104659-26-029004) |url=https://www.sec.gov/Archives/edgar/data/1227636/000110465926029004/stim-20251231x10k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-17}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.